Background The prevalence of metabolic syndrome and its possible impact on the severity of liver histological lesions have not been studied prospectively in chronic liver diseases.
Kafiri +6 more
core
The role of tryptophan hydroxylase‐1 in metabolic dysfunction‐associated steatotic liver disease
Silencing hepatic tryptophan hydroxylase 1 (TPH1) alleviated diet‐induced steatotic liver disease by reducing lipid accumulation, oxidative stress, inflammation, fibrosis, and hepatocyte apoptosis. These protective effects were mediated, at least in part, through restoration of Parkin‐dependent mitochondrial autophagy, identifying hepatic TPH1 as a ...
Shuangzhen Jia +3 more
wiley +1 more source
Metabolic Dysfunction-Associated Steatohepatitis: Is There Evidence for Fractured CD4+ T-Cell Tolerance in the Immunopathogenesis. [PDF]
Russi AE, DeBosch BJ.
europepmc +1 more source
Diagnosis of Portal Hypertension: Advancing Towards Non‐Invasive Solutions
This review systematically summarizes a full spectrum of non‐invasive diagnostic approaches for portal hypertension (PH), including imaging modalities, elastography, serum biomarkers, composite scoring systems and endoscopic ultrasound‐guided portal pressure gradient (EUS‐PPG), and analyzes their performance across different liver disease etiologies ...
Lijia Yin, Huikuan Chu, Ling Yang
wiley +1 more source
Commentary: Wogonoside alleviates metabolic dysfunction-associated steatohepatitis by modulating AMPK and xCT/GPX4 pathways to restrain lipid dysregulation and ferroptosis. [PDF]
Fang Y, Xing L.
europepmc +1 more source
XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis
Aleksandra Deczkowska +31 more
semanticscholar +1 more source
Epigenetic Regulation of Liver Fibrosis: Mechanisms and Therapeutic Implications
This review synthesizes the epigenetic mechanisms—DNA methylation, histone modifications, and non‐coding RNAs—that drive hepatic stellate cell activation and the progression of liver fibrosis. It further evaluates emerging therapeutic strategies targeting these epigenetic regulators, including DNA methyltransferase and histone deacetylase inhibitors ...
Maryam Jadid Tavaf +8 more
wiley +1 more source
Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): A systematic review and meta-analysis. [PDF]
Alfawaz M +9 more
europepmc +1 more source
A new marker for lipid peroxidation: Serum paraoxonase activity in non-alcoholic steatohepatitis
Background/aims: Relationship between hepatic antioxidant paraoxonase 1 (PON1) activity, lipid peroxidation and liver injury was investigated in patients with non-alcoholic steatohepatitis.
Yücesoy, Mehmet +4 more
core
Recompensation of Cirrhosis: A New Treatment‐Related Disease State
This perspective article conceptualizes recompensation of cirrhosis as a distinct treatment‐related disease state rather than mere transient clinical improvement after etiology‐directed therapy, and further proposes a four‐state classification including compensated cirrhosis, stable recompensation, unstable recompensation, and persistent decompensation
Wentao Tan +5 more
wiley +1 more source

